Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Acquired by Thrivent Financial for Lutherans

Thrivent Financial for Lutherans grew its position in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 446.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,498 shares of the medical research company's stock after acquiring an additional 3,675 shares during the period. Thrivent Financial for Lutherans' holdings in Bio-Rad Laboratories were worth $1,505,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in BIO. UMB Bank n.a. lifted its holdings in Bio-Rad Laboratories by 140.6% in the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company's stock valued at $26,000 after acquiring an additional 45 shares during the period. Capital Advisors Ltd. LLC lifted its stake in shares of Bio-Rad Laboratories by 193.8% in the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company's stock valued at $26,000 after purchasing an additional 62 shares during the period. Wealth Enhancement Advisory Services LLC boosted its holdings in Bio-Rad Laboratories by 9.5% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 947 shares of the medical research company's stock worth $259,000 after buying an additional 82 shares in the last quarter. GAMMA Investing LLC grew its position in Bio-Rad Laboratories by 37.2% during the second quarter. GAMMA Investing LLC now owns 321 shares of the medical research company's stock worth $88,000 after buying an additional 87 shares during the period. Finally, Creative Planning increased its holdings in Bio-Rad Laboratories by 6.0% in the third quarter. Creative Planning now owns 1,632 shares of the medical research company's stock valued at $546,000 after buying an additional 93 shares in the last quarter. 65.24% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP James Barry sold 623 shares of the stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total transaction of $205,895.27. Following the completion of the sale, the executive vice president now owns 147 shares of the company's stock, valued at approximately $48,582.03. This represents a 80.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Andrew J. Last sold 3,000 shares of Bio-Rad Laboratories stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the transaction, the chief operating officer now directly owns 7,559 shares in the company, valued at approximately $2,494,016.46. This trade represents a 28.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 17.06% of the stock is owned by corporate insiders.

Bio-Rad Laboratories Trading Up 0.6 %

Shares of Bio-Rad Laboratories stock traded up $2.05 during mid-day trading on Friday, hitting $340.53. 78,237 shares of the stock were exchanged, compared to its average volume of 197,129. The company has a 50-day simple moving average of $340.77 and a 200 day simple moving average of $317.92. The company has a current ratio of 6.14, a quick ratio of 4.52 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $9.53 billion, a price-to-earnings ratio of -12.46 and a beta of 0.93. Bio-Rad Laboratories, Inc. has a twelve month low of $262.12 and a twelve month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 earnings per share for the quarter, beating the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The company had revenue of $649.70 million during the quarter, compared to the consensus estimate of $628.18 million. During the same period in the previous year, the firm posted $2.33 EPS. Bio-Rad Laboratories's revenue was up 2.8% on a year-over-year basis. Research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.29 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on BIO shares. Wells Fargo & Company initiated coverage on Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an "equal weight" rating and a $340.00 price target on the stock. Royal Bank of Canada upped their target price on Bio-Rad Laboratories from $446.00 to $469.00 and gave the company an "outperform" rating in a report on Thursday, October 31st. Citigroup lifted their price target on Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a "buy" rating in a research note on Thursday, October 31st. Finally, StockNews.com upgraded shares of Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, November 1st. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $391.80.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.